Connect Biopharma Announces Positive Phase 2 Data for COPD Exacerbation Treatment Rademikibart
The company reported positive preliminary topline data from its Phase 2 study showing rademikibart significantly reduced COPD exacerbations and hospitalizations, potentially setting up a pivotal Phase 3 program.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed